Kailera Therapeutics (NASDAQ:KLRA) Stock Price Down 5.6% – Should You Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price was down 5.6% on Thursday. The company traded as low as $10.69 and last traded at $10.78. 113,294 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 806,460 shares. The stock had previously closed at $11.42.

Wall Street Analyst Weigh In

Separately, Weiss Ratings started coverage on shares of Kailera Therapeutics in a research report on Friday, August 14th. They set a “sell (d)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Performance

The firm has a market capitalization of $1.44 billion and a price-to-earnings ratio of -0.00. The stock’s fifty day simple moving average is $15.93.

Kailera Therapeutics (NASDAQ:KLRA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). As a group, equities research analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Atlas Venture Life Science Advisors LLC purchased a new position in Kailera Therapeutics during the 2nd quarter valued at about $113,923,000. Wellington Management Group LLP bought a new stake in shares of Kailera Therapeutics during the second quarter valued at about $64,308,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Kailera Therapeutics in the second quarter worth about $24,233,000. State Street Corp purchased a new stake in shares of Kailera Therapeutics in the second quarter worth about $19,126,000. Finally, Squarepoint Ops LLC bought a new position in shares of Kailera Therapeutics in the second quarter valued at approximately $993,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.